“The current scenario has exposed some structural weaknesses from the EU’s medicines offer chain in addition to a superior dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides said. She encouraged that offer chain problems be dealt with within an EU pharmaceutical technique expected to generally be